Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

6.53USD
2:59pm EDT
Price Change (% chg)

$-0.04 (-0.61%)
Prev Close
$6.57
Open
$6.56
Day's High
$6.56
Day's Low
$6.39
Volume
19,844
Avg. Vol
113,049
52-wk High
$7.15
52-wk Low
$4.91

DEPO.OQ

Chart for DEPO.OQ

About

Depomed, Inc. (Depomed) is a specialty pharmaceutical company initially focused on neurology, pain and other diseases of the central nervous system. In January 2011, the United States Food and Drug Administration (FDA) approved Gralise (gabapentin) once-daily tablets for the management of postherpetic neuralgia. The Company is... (more)

Overall

Beta: 1.53
Market Cap (Mil.): $371.23
Shares Outstanding (Mil.): 56.50
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 38.06 37.87
EPS (TTM): -0.47 -- --
ROI: -24.12 19.42 18.70
ROE: -29.52 20.10 19.53
Search Stocks

FDA advisors vote against two drugs for menopausal hot flashes

WASHINGTON - Advisers to the Food and Drug Administration on Monday voted against approval of two drugs designed to reduce the frequency and severity of hot flashes associated with menopause, concluding that neither conferred enough benefit to offset their risk.

04 Mar 2013

UPDATE 3-FDA advisors vote against two drugs for menopausal hot flashes

* U.S. FDA advisory panel votes to reject Depomed's Sefelsa * Panel also rejects Noven Pharmaceuticals menopause drug * Advisors say neither drug confers enough benefit * Depomed shares fall 9.8 percent (Adds panel's rejection of Noven drug) By Toni Clarke WASHINGTON, March 4 - Advisers to the U.S. Food and Drug Administration on Monday voted against approval of two drugs designed to reduce the frequency and severity of hot flashes associated with menopause, concl

04 Mar 2013

BRIEF-Depomed falls after FDA advisory committee rejects menopause drug

NEW YORK, March 4 - Depomed Inc : * Resumes trading down 15.8 percent to $5.50 after FDA advisory committee rejects menopause drug

04 Mar 2013

FDA advisers vote against approval for Depomed's menopause drug

March 4 - Advisers to the U.S. Food and Drug Administration on Monday recommended the agency reject a drug made by Depomed Inc to reduce the frequency and severity of hot flashes associated with menopause.

04 Mar 2013

FDA staff say two non-hormonal hot flashes drugs show some efficacy

- Food and Drug Administration staff said experimental drugs by Depomed Inc and Hisamitsu Pharmaceutical Co Inc showed efficacy in reducing menopausal hot flashes, and highlighted no new risks in comments issued on Thursday.

28 Feb 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks